376 related articles for article (PubMed ID: 12142559)
1. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
3. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
Chang AE; Li Q; Jiang G; Sayre DM; Braun TM; Redman BG
J Clin Oncol; 2003 Mar; 21(5):884-90. PubMed ID: 12610189
[TBL] [Abstract][Full Text] [Related]
5. Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine.
Meijer SL; Dols A; Hu HM; Chu Y; Romero P; Urba WJ; Fox BA
Cell Immunol; 2004 Feb; 227(2):93-102. PubMed ID: 15135291
[TBL] [Abstract][Full Text] [Related]
6. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.
Hu HM; Urba WJ; Fox BA
J Immunol; 1998 Sep; 161(6):3033-41. PubMed ID: 9743368
[TBL] [Abstract][Full Text] [Related]
7. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
[TBL] [Abstract][Full Text] [Related]
8. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.
Kurokawa T; Oelke M; Mackensen A
Int J Cancer; 2001 Mar; 91(6):749-56. PubMed ID: 11275975
[TBL] [Abstract][Full Text] [Related]
9. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
Powell DJ; Dudley ME; Hogan KA; Wunderlich JR; Rosenberg SA
J Immunol; 2006 Nov; 177(9):6527-39. PubMed ID: 17056585
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
[TBL] [Abstract][Full Text] [Related]
13. Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies.
Winter H; Hu HM; Poehlein CH; Huntzicker E; Osterholzer JJ; Bashy J; Lashley D; Lowe B; Yamada J; Alvord G; Urba WJ; Fox BA
Immunology; 2003 Mar; 108(3):409-19. PubMed ID: 12603608
[TBL] [Abstract][Full Text] [Related]
14. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
[TBL] [Abstract][Full Text] [Related]
15. B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma.
Antonia SJ; Seigne JD
World J Urol; 2000 Apr; 18(2):157-63. PubMed ID: 10854153
[TBL] [Abstract][Full Text] [Related]
16. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene.
Chang AE; Sondak VK; Bishop DK; Nickoloff BJ; Mulligan RC; Mulé JJ
Hum Gene Ther; 1996 Apr; 7(6):773-92. PubMed ID: 9053030
[No Abstract] [Full Text] [Related]
18. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
19. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
[No Abstract] [Full Text] [Related]
20. Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro.
Imro MA; Dellabona P; Manici S; Heltai S; Consogno G; Bellone M; Rugarli C; Protti MP
Hum Gene Ther; 1998 Jun; 9(9):1335-44. PubMed ID: 9650618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]